[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[3]
|
Zhang, Z.M., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. https://doi.org/10.1016/j.ijsu.2015.05.009
|
[4]
|
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
|
[5]
|
Ng, J. and Wu, J. (2012) Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas in the United States: Similarities and Differences. Hepatitis Monthly, 12, e7635. https://doi.org/10.5812/hepatmon.7635
|
[6]
|
Lu, J., Zhang, X., Zhong, B., et al. (2019) Management of Patients with Hepatocellular Carcinoma and Portal Vein Tumour Thrombosis: Comparing East and West. The Lancet Gastroenterology & Hepatology, 4, 721-730.
https://doi.org/10.1016/S2468-1253(19)30178-5
|
[7]
|
Ikai, I., Yamamoto, Y., Yamamoto, N., et al. (2003) Results of Hepatic Resection for Hepatocellular Carcinoma Invading Major Portal and/or Hepatic Veins. Surgical Oncology Clinics of North America, 12, 65-75.
https://doi.org/10.1016/S1055-3207(02)00082-0
|
[8]
|
程树群, 吴孟超, 陈汉, 等. 肝癌门静脉癌栓分型的影像学意义[J]. 中华普通外科杂志, 2004, 19(4): 200-201.
|
[9]
|
Niu, Z.-J., Ma, Y.-L, Kang, P., et al. (2012) Transarterial Chemoembolization Compared with Conservative Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Using a New Classification. Medical Oncology, 29, 2992-2997. https://doi.org/10.1007/s12032-011-0145-0
|
[10]
|
Shi, J., Lai, E.C., Li, N., et al. (2011) A New Classification for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepato-Biliary-Pancreatic Sciences, 18, 74-80. https://doi.org/10.1007/s00534-010-0314-0
|
[11]
|
Kokudo, T., Hasegawa, K., Matsuyama, Y., et al. (2016) Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Hepatology, 65, 938-943.
https://doi.org/10.1016/j.jhep.2016.05.044
|
[12]
|
中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
|
[13]
|
Zhang, X.-P., Wang, K., Wei, X.-B., et al. (2019) An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion after R0 Liver Resection: A Large-Scale, Multicenter Study. Oncologist, 24, e1476-e1488.
https://doi.org/10.1634/theoncologist.2018-0868
|
[14]
|
Zheng, N., Wei, X., Zhang, D., et al. (2016) Hepatic Re-section or Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Medicine, 95, e3959. https://doi.org/10.1097/MD.0000000000003959
|
[15]
|
Wang, K., Guo, W.X., Chen, M.S., et al. (2016) Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine, 95, e3015.
https://doi.org/10.1097/MD.0000000000003015
|
[16]
|
Yu, J.I. and Park, H.C. (2016) Radiotherapy as Valid Mo-dality for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. World Journal of Gastroenterology, 22, 6851-6863. https://doi.org/10.3748/wjg.v22.i30.6851
|
[17]
|
Wei, X., Jiang, Y., Zhang, X., et al. (2019) Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 37, 2141-2151. https://doi.org/10.1200/JCO.18.02184
|
[18]
|
Hamaoka, M., Kobayashi, T., Kuroda, S., et al. (2017) Hepatectomy after Down-Staging of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Using Chemoradiotherapy: A Retrospective Cohort Study. International Journal of Surgery, 44, 223-228. https://doi.org/10.1016/j.ijsu.2017.06.082
|
[19]
|
Byun, H.K., Kim, H.J., Im, Y.R., et al. (2019) Dose Escalation by Intensity Modulated Radiotherapy in Liver-Directed Concurrent Chemoradiotherapy for Locally Advanced BCLC Stage C Hepatocellular Carcinoma. Radiotherapy and Oncology, 133, 1-8. https://doi.org/10.1016/j.radonc.2018.12.025
|
[20]
|
Li, Y., Li, H., Hu, H., Yuan, H. and Zhao, Y. (2020) Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with either 125I Seed Implantation or Apatinib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Retrospective Comparative Study. Journal of Cancer Research and Therapeutics, 16, 1691-1697.
|
[21]
|
Zhang, Z.-H., Zhang, W., Gu, J.-Y., et al. (2018) Treatment of Hepatocellular Carcinoma with Tumor Thrombus with the Use of Iodine-125 Seed Strand Implantation and Transarterial Chemoembolization: A Propensity-Score Analysis. Journal of Vascular and Interventional Radiology, 29, 1085-1093. https://doi.org/10.1016/j.jvir.2018.02.013
|
[22]
|
Yang, M., Fang, Z., Yan, Z., et al. (2014) Transarterial Chemoembolisation (TACE) Combined with Endovascular Implantation of an Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis versus TACE Alone: A Two-Arm, Randomised Clinical Trial. Journal of Cancer Research and Clinical Oncology, 140, 211-219. https://doi.org/10.1007/s00432-013-1568-0
|
[23]
|
Garin, E., Rolland, Y., Edeline, J., et al. (2015) Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Journal of Nuclear Medicine, 56, 339-346. https://doi.org/10.2967/jnumed.114.145177
|
[24]
|
Edeline, J., Crouzet, L., Campillo-Gimenez, B., et al. (2016) Selective Internal Radiation Therapy Compared with Sorafenib for Hepatocellular Carcinoma with Portal Vein Thrombosis. European Journal of Nuclear Medicine and Molecular Imaging, 43, 635-643. https://doi.org/10.1007/s00259-015-3210-7
|
[25]
|
Martelletti, C., Ricotti, A., Gesualdo, M., et al. (2021) Radioembolization vs Sorafenib in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score and Bayesian Analysis. Journal of Digestive Diseases, 22, 496-502. https://doi.org/10.1111/1751-2980.13030
|
[26]
|
Wang, J.-C., Xia, A.-L., Xu, Y. and Lu, X.-J. (2019) Comprehen-sive Treatments for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Cellular Physiology, 234, 1062-1070. https://doi.org/10.1002/jcp.27324
|
[27]
|
Chung, G.E., Lee, J.-H., Kim, H.Y., et al. (2011) Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 258, 627-634. https://doi.org/10.1148/radiol.10101058
|
[28]
|
Yoon, S.M., Ryoo, B.-Y., Lee, S.J., et al. (2018) Efficacy and Safety of Transarterial Chemoembolization plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncology, 4, 661-669. https://doi.org/10.1001/jamaoncol.2017.5847
|
[29]
|
Fan, J., Tang, Z.-Y., Yu, Y.-Q., et al. (1998) Improved Survival with Resection after Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma. Digestive Surgery, 15, 674-678.
https://doi.org/10.1159/000018676
|
[30]
|
He, M.-K., Le, Y., Li, Q.-J., et al. (2017) Hepatic Artery Infusion Chem-otherapy Using mFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, 83. https://doi.org/10.1186/s40880-017-0251-2
|
[31]
|
Hu, J., Bao, Q., Cao, G., et al. (2020) Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. CardioVascular and Interventional Radiology, 43, 996-1005.
https://doi.org/10.1007/s00270-019-02406-3
|
[32]
|
Yoon, H.I., Song, K.J., Lee, I.J., et al. (2016) Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Research and Treatment, 48, 190-197. https://doi.org/10.4143/crt.2014.276
|
[33]
|
Lyu, N., Kong, Y., Mu, L., et al. (2018) Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin vs. Sorafenib for Advanced Hepatocellular Carcinoma. Journal of Hepatology, 69, 60-69.
https://doi.org/10.1016/j.jhep.2018.02.008
|
[34]
|
Nagai, H., Mukozu, T., Ogino, Y., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2277.
|
[35]
|
Lee, H.S., Choi, G.H., Choi, J.S., et al. (2014) Surgical Resection after Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. Annals of Surgical Oncology, 21, 3646-3653.
https://doi.org/10.1245/s10434-014-3652-3
|
[36]
|
Chong, J.U., Choi, G.H., Han, D.H., et al. (2018) Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 25, 3308-3315. https://doi.org/10.1245/s10434-018-6653-9
|
[37]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173.
https://doi.org/10.1016/S0140-6736(18)30207-1
|
[38]
|
Abou-Alfa, G.K., Meyer, T., Cheng, A.L., et al. (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. The New England Journal of Medicine, 379, 54-63. https://doi.org/10.1056/NEJMoa1717002
|
[39]
|
Cheng, A.-L., Kang, Y.-K., Chen, Z., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
|
[40]
|
Mohr, R., Jost-Brinkmann, F., Ozdirik, B., et al. (2021) Lessons from Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology, 12, Article 652172. https://doi.org/10.3389/fimmu.2021.652172
|
[41]
|
Huang, C., Zhu, X.-D., Shen, Y.-H., et al. (2021) Organ Specific Responses to First-Line Lenvatinib plus Anti-PD-1 Antibodies in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. Biomarker Research, 9, Article No. 19. https://doi.org/10.1186/s40364-021-00274-z
|
[42]
|
He, M., Li, Q., Zou, R., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[43]
|
He, M.-K., Liang, R.-B., Zhao, Y., et al. (2021) Lenvatinib, Toripalimab, plus Hepatic Arterial Infusion chemotherapy versus Lenvatinib Alone for Advanced Hepatocellular Car-cinoma. Therapeutic Advances in Medical Oncology, 13, Article ID: 17588359211002720. https://doi.org/10.1177/17588359211002720
|